Naringenin relieves paclitaxel-induced pain by suppressing calcitonin gene-related peptide signalling and enhances the anti-tumour action of paclitaxel.
Chen PanYuhao XuZongsheng JiangChengjiang FanZhexi ChiYu ZhangMengmeng MiaoYuxuan RenZiyi WuLinbin XuChangqing MeiQingge ChenYang XiXiaowei ChenPublished in: British journal of pharmacology (2024)
Naringenin's anti-nociceptive mechanism involves CGRP signalling and neuroimmunoregulation. Furthermore, naringenin facilitates paclitaxel's anti-tumour action, possibly involving apoptosis. This study demonstrates naringenin's potential as a supplementary treatment in cancer therapy by mitigating side effects and potentiating efficacy of chemotherapy.
Keyphrases
- cancer therapy
- neuropathic pain
- chronic pain
- oxidative stress
- chemotherapy induced
- drug delivery
- cell death
- copy number
- genome wide
- spinal cord injury
- combination therapy
- cell cycle arrest
- risk assessment
- dna methylation
- locally advanced
- gene expression
- climate change
- signaling pathway
- stress induced
- smoking cessation